Publication digest

CDK4/6 inhibitors in combination with endocrine therapy as potential therapies for treating high-risk early breast cancer patients

Does addition of abemaciclib to endocrine therapy (ET) as an adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer patients provide additional benefits versus treatment with ET alone?

Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020:JCO2002514.

• Up to 30% of patients with high-risk clinical and/or pathological features of HR+/HER2- early breast cancer (EBC) may experience recurrence¹
• Superior treatment options are required to prevent early recurrence and development of metastases for these patients¹
• Abemaciclib in combination with endocrine therapy is the first CDK4/6 inhibitor to demonstrate significant improvement in invasive disease-free survival (IDFS) patients¹

Almost all patients (90%) with breast cancer are diagnosed at an early stage, of whom approximately 70% have HR+, HER2- cancers^2,3. Adjuvant endocrine therapy (ET) which is the standard treatment for HR+/HER2- early breast cancer (EBC) has been linked to reducing the risk of recurrence and death⁴. However, recurrence for patients with high-risk features is high and it is therefore very important to optimise therapy to prevent early recurrences and metastases for these patients^1,5.

CDK4/6 inhibitors are currently being used in combination with hormone therapy to treat HR+/HER2- advanced breast cancers⁶.

CDK4/6 inhibitors are currently being used in combination with hormone therapy to treat HR+/HER2- advanced breast cancers⁶ but whether there is an additional benefit for such treatment in patients with HR+/HER2- EBC is yet to be confirmed. The open-label, phase III monarchE trial discussed here included patients with HR+/HER2-, high-risk EBC to evaluate the combination of the CDK 4/6 inhibitor abemaciclib and standard ET in the adjuvant setting. It concluded that there was a significant improvement in invasive-disease free survival (IDFS) after adding abemaciclib and, if approved, abemaciclib could become the new standard of care for this patient population¹.

Johnston et al report on 5,637 patients (both male and female ≥ 18 years of age with HR+ and HER2- disease) from 603 sites in 38 countries who received either abemaciclib (150 mg twice daily) + ET (n=2,808) or ET alone (n=2,829) as a control arm. The primary endpoint was IDFS per the STEEP criteria and measured from the date of randomisation to the date of the first occurrence of recurrence, death due to any cause, contralateral invasive breast cancer or secondary primary non-breast invasive cancer¹. The secondary endpoint was the distance relapse-free survival (DRFS), the time from randomisation to distant recurrence or death from any cause, and other secondary endpoints included overall survival, safety, pharmacokinetics, and patient-reported outcomes. Efficacy analyses were carried out on an ITT population with a primary objective to test the superiority of abemaciclib + ET vs ET on IDFS, and the safety analysed in all patients who received at least one dose of study treatment¹.

The monarchE study findings indicate that the addition of abemaciclib to standard adjuvant ET resulted in a statistically significant improvement in efficacy. IDFS events were lower in the abemaciclib arm (4.8%) vs the control arm (6.6%) and with higher 2-year IDFS rates (92.2% vs 88,7%, respectively) (P=0.01). Greater improvement was also observed in DRFS after abemaciclib + ET treatment vs ET alone (P=0.01), with 2-year DRFS rates of 93.6% (abemaciclib) vs 90.3% (control)¹. Safety data were consistent with the known safety profile of abemaciclib, with the most common adverse events being diarrhoea, neutropenia, and fatigue in the abemaciclib arm and arthralgia, hot flush and fatigue in the control arm. Serious adverse events (SAEs) also occurred in 12.3% of patients in the abemaciclib arm vs 7.2% of patients in the control treatment, with the most common SAE reported in both arms being pneumonia¹.

If approved, abemaciclib added to standard adjuvant ET could become a new standard of care for patients with HR+, HER2- high-risk EBC¹.

Of note, the monarchE study is the first study to report that adding a CDK4/6 inhibitor to ET in the adjuvant setting provides an additional benefit for patients with HR+, HER2- EBC. The results evidently revealed a significant improvement in IDFS following abemaciclib treatment in patients with high-risk EBC in the adjuvant setting. There was a 25% risk reduction in developing IDFS events compared to ET alone and a 3.5% absolute improvement in IDFS rates, with safety consistent with the known safety profile of abemaciclib¹. As a result of this study, if abemaciclib added to standard adjuvant ET is approved, it could become a new standard of care for patients with HR+, HER2- high-risk EBC¹.

References

1. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;JCO.20.02514.
2. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. JNCI J Natl Cancer Inst. 2014;106(5):dju055.
3. Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). Breast. 2018;39:131–138.
4. National Comprehensive Cancer Network. Nationa Comprehensive Cancer Network: Breast Cancer (version 4.2020). 2020. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 December 2020.
5. Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong JH, et al. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Res Treat. 2018;168(1):69–77.
6. Shah M, Nunes MR, Stearns V. CDK4/6 inhibitors: Game changers in the management of hormone receptor– positive advanced breast cancer? Oncol (United States). 2018;32(5):216–222.